Anti-Human CD38/ADPRC 1 Nanobody (SAA2057) (HB691053)

Datasheet Share product Copy info

Price(USD): $

Spec:

20ug
50ug
100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.

HB691053

Description

Anti-Human CD38/ADPRC 1 Nanobody (SAA2057) [SAA2057] (HB691053) is a alpaca monoclonal antibody detecting ADPRC 1 in ELISA. Suitable for Human.

Species reactivity

Human

Applications

ELISA

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clone ID

SAA2057

Clonality

Monoclonal

Target

Cyclic ADP-ribose hydrolase 1, ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, 2'-phospho-ADP-ribosyl cyclase/2'-phospho-cyclic-ADP-ribose transferase, T10, 2'-phospho-cyclic-ADP-ribose transferase, CD38, ADPRC 1, ADP-ribosyl cyclase 1, 2'-phospho-ADP-ribosyl cyclase

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Purified by Nickel column.

Accession

P28907

RRID

Anti-Human CD38/ADPRC 1 Nanobody (SAA2057) (abinScience Cat# HB691053, RRID:AB_3729052)

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Background

ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38/ADPRC 1) is a ~34 kDa protein. Multifunctional transmembrane glycoprotein able to exert enzymatic activities and also to mobilize calcium, to transduce signals, to adhere to hyaluronan and to other ligands. Synthesizes cyclic ADP-ribose (cADPR), a second messenger for glucose-induced insulin secretion. Synthesizes the Ca(2+) mobilizer nicotinate-adenine dinucleotide phosphate, NAADP(+), from 2'-phospho-cADPR and nicotinic acid, as well as from NADP(+) and nicotinic acid. At both pH 5.0 and pH 7.4 preferentially transforms 2'-phospho-cADPR into NAADP(+), while preferentially cleaving NADP(+) to cADPR and ADPRP rather than into NADDP(+). Has cADPR hydrolase activity. CD38 is the therapeutic target of daratumumab (Darzalex).

1. Tohgo, A. et al. (1994) The Journal of biological chemistry 269, 28555-7. PMID: 7961800

2. Takasawa, S. et al. (1993) The Journal of biological chemistry 268, 26052-4. PMID: 8253715

3. Moreschi, I. et al. (2006) Biochemical and biophysical research communications 345, 573-80. PMID: 16690024

4. Deaglio, S. et al. (1998) Journal of immunology (Baltimore, Md. : 1950) 160, 395-402. PMID: 9551996

5. Frasca, L. et al. (2006) Blood 107, 2392-9. PMID: 16293598

6. Deaglio, S. et al. (2001) FASEB journal : official publication of the Federation of American Societies for Experimental Biology 15, 580-2. PMID: 11259373

Note

For research use only.

Images